Terms: = Uterine cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
17 results:
1. Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer.
Kang SW; Kang OJ; Lee JY; Kim H; Jung H; Kim H; Lee SW; Kim YM; Choi EK
PLoS One; 2024; 19(2):e0298815. PubMed ID: 38363779
[TBL] [Abstract] [Full Text] [Related]
2. In-silico analysis reveals Quinic acid as a multitargeted inhibitor against Cervical cancer.
Ahmad S; Sayeed S; Bano N; Sheikh K; Raza K
J Biomol Struct Dyn; 2023 Nov; 41(19):9770-9786. PubMed ID: 36379678
[TBL] [Abstract] [Full Text] [Related]
3. Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia.
Matsuo K; Violette CJ; Mandelbaum RS; Harris CA; Tavakoli A; Klar M; Shoupe D; Roman LD
Am J Obstet Gynecol; 2022 Aug; 227(2):255.e1-255.e18. PubMed ID: 35487326
[TBL] [Abstract] [Full Text] [Related]
4. Is hysterectomy necessary for the treatment of preinvasive stratified mucin producing intraepithelial lesions of the cervix?
Kahn R; Zhou ZN; Goyal A; Gamble C; Nicholson N; Caputo TA; Holcomb K; Frey MK; Chapman-Davis E
Int J Gynecol Cancer; 2020 Sep; 30(9):1298-1302. PubMed ID: 32448806
[TBL] [Abstract] [Full Text] [Related]
5. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract] [Full Text] [Related]
6. Delayed IL-21 treatment preferentially expands peptide-specific CD8
Kim SH; Park SY; Lim MC; Lee ES; Lee EG; Han SE; Kim YH; Kwon BS; Choi BK
Immunotherapy; 2019 Apr; 11(6):497-513. PubMed ID: 30760061
[TBL] [Abstract] [Full Text] [Related]
7. hla-a*30:01 and hla-a*33:03 are the protective alleles while hla-a*01:01 serves as the susceptible gene for cervical cancer patients in Xinjiang, China.
Alifu M; Hu YH; Dong T; Wang RZ
J Cancer Res Ther; 2018; 14(6):1266-1272. PubMed ID: 30488842
[TBL] [Abstract] [Full Text] [Related]
8. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Jin BY; Campbell TE; Draper LM; Stevanović S; Weissbrich B; Yu Z; Restifo NP; Rosenberg SA; Trimble CL; Hinrichs CS
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669936
[TBL] [Abstract] [Full Text] [Related]
9. Somatic Host Cell Alterations in HPV Carcinogenesis.
Litwin TR; Clarke MA; Dean M; Wentzensen N
Viruses; 2017 Aug; 9(8):. PubMed ID: 28771191
[TBL] [Abstract] [Full Text] [Related]
10. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract] [Full Text] [Related]
11. High-dose-rate interstitial brachytherapy for gynecologic malignancies.
Beriwal S; Bhatnagar A; Heron DE; Selvaraj R; Mogus R; Kim H; Gerszten K; Kelley J; Edwards RP
Brachytherapy; 2006; 5(4):218-22. PubMed ID: 17118313
[TBL] [Abstract] [Full Text] [Related]
12. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.
Brooks SE; Zhan M; Cote T; Baquet CR
Gynecol Oncol; 2004 Apr; 93(1):204-8. PubMed ID: 15047237
[TBL] [Abstract] [Full Text] [Related]
13. Human T-cell responses to hla-a-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7.
Rudolf MP; Man S; Melief CJ; Sette A; Kast WM
Clin Cancer Res; 2001 Mar; 7(3 Suppl):788s-795s. PubMed ID: 11300474
[TBL] [Abstract] [Full Text] [Related]
14. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
Cornelison TL
Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
[TBL] [Abstract] [Full Text] [Related]
15. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
van Driel WJ; Ressing ME; Kenter GG; Brandt RM; Krul EJ; van Rossum AB; Schuuring E; Offringa R; Bauknecht T; Tamm-Hermelink A; van Dam PA; Fleuren GJ; Kast WM; Melief CJ; Trimbos JB
Eur J Cancer; 1999 Jun; 35(6):946-52. PubMed ID: 10533477
[TBL] [Abstract] [Full Text] [Related]
16. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract] [Full Text] [Related]
17. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
Ressing ME; van Driel WJ; Celis E; Sette A; Brandt MP; Hartman M; Anholts JD; Schreuder GM; ter Harmsel WB; Fleuren GJ; Trimbos BJ; Kast WM; Melief CJ
Cancer Res; 1996 Feb; 56(3):582-8. PubMed ID: 8564975
[TBL] [Abstract] [Full Text] [Related]